CN101012458A - 表达系统 - Google Patents

表达系统 Download PDF

Info

Publication number
CN101012458A
CN101012458A CNA2006101290967A CN200610129096A CN101012458A CN 101012458 A CN101012458 A CN 101012458A CN A2006101290967 A CNA2006101290967 A CN A2006101290967A CN 200610129096 A CN200610129096 A CN 200610129096A CN 101012458 A CN101012458 A CN 101012458A
Authority
CN
China
Prior art keywords
ser
nucleic acid
asn
thr
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006101290967A
Other languages
English (en)
Chinese (zh)
Inventor
E·D·威廉森
J·米勒
N·J·瓦尔克
L·W·J·拜利
P·T·霍尔登
H·C·弗利克-史密斯
H·L·布利芬特
R·W·蒂特巴尔
A·W·托平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UK Secretary of State for Defence
Original Assignee
UK Secretary of State for Defence
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UK Secretary of State for Defence filed Critical UK Secretary of State for Defence
Publication of CN101012458A publication Critical patent/CN101012458A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2006101290967A 2000-07-08 2001-07-06 表达系统 Pending CN101012458A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0016702.3A GB0016702D0 (en) 2000-07-08 2000-07-08 Expression system
GB0016702.3 2000-07-08

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB018124097A Division CN1322134C (zh) 2000-07-08 2001-07-06 表达系统

Publications (1)

Publication Number Publication Date
CN101012458A true CN101012458A (zh) 2007-08-08

Family

ID=9895205

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2006101290967A Pending CN101012458A (zh) 2000-07-08 2001-07-06 表达系统
CNB018124097A Expired - Fee Related CN1322134C (zh) 2000-07-08 2001-07-06 表达系统

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB018124097A Expired - Fee Related CN1322134C (zh) 2000-07-08 2001-07-06 表达系统

Country Status (10)

Country Link
US (3) US7537771B2 (enExample)
EP (2) EP1808489B1 (enExample)
JP (2) JP2004502460A (enExample)
CN (2) CN101012458A (enExample)
AU (1) AU2007201553B8 (enExample)
CA (2) CA2658217A1 (enExample)
GB (1) GB0016702D0 (enExample)
RU (2) RU2385348C2 (enExample)
WO (1) WO2002004646A1 (enExample)
ZA (1) ZA200210206B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0016702D0 (en) 2000-07-08 2000-08-23 Secr Defence Brit Expression system
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
WO2004024067A2 (en) * 2002-09-10 2004-03-25 Vical Incorporated Codon-optimized polynucleotide-based vaccines against bacillus anthracis infection
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
AU2003303307B2 (en) * 2002-11-15 2006-12-07 Gen-Probe Incorporated Assay and compositions for detection of bacillus anthracis nucleic acid
WO2005026203A2 (en) 2003-09-18 2005-03-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dna promoters and anthrax vaccines
FR2860005A1 (fr) * 2003-09-23 2005-03-25 Univ Aix Marseille Ii Methode de detection d'agents bacteriens ou viraux de bioterrorisme
WO2005030991A1 (fr) * 2003-09-23 2005-04-07 Universite De La Mediterranee (Aix-Marseille Ii) Methode de detection d’agents bacteriens ou viraux de bioterrorisme
GB0401036D0 (en) * 2004-01-17 2004-02-18 Royal Holloway University Of L Improvements in or relating to vaccination
US8101735B2 (en) 2004-06-16 2012-01-24 Health Protection Agency Preparation of protective antigen
US7355027B2 (en) 2004-06-16 2008-04-08 Dynport Vaccine Company Llc Bacillus anthracis protective antigen
US8603824B2 (en) 2004-07-26 2013-12-10 Pfenex, Inc. Process for improved protein expression by strain engineering
CN100336908C (zh) * 2004-09-10 2007-09-12 中国人民解放军军事医学科学院微生物流行病研究所 一种制备重组炭疽保护性抗原的方法及其专用表达质粒
WO2006068647A1 (en) * 2004-12-20 2006-06-29 United States Army Medical Research And Materiel Command Internal positive control for probe-based nucleic acid molecule assays and methods of making and using thereof
GB0504940D0 (en) * 2005-03-10 2005-04-20 Secr Defence Vaccine formulation
WO2008048289A2 (en) 2005-11-14 2008-04-24 University Of Maryland Biotechnology Institute Off. Of Research Admin./Tech. Dev. Salmonella based oral vaccines for anthrax
GB0525213D0 (en) * 2005-12-12 2006-01-18 Secr Defence Vaccine
US20070202117A1 (en) * 2005-12-22 2007-08-30 Herman Groen Compositions and Methods Of Modulating the Immune Response
GB0607462D0 (en) 2006-04-13 2006-05-24 Avecia Ltd Assay
JP2008231063A (ja) * 2007-03-22 2008-10-02 Takano Foods Kk 納豆菌ワクチン
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
CA2964910C (en) 2007-04-27 2018-01-09 Pfenex Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
WO2010038076A1 (en) * 2008-10-02 2010-04-08 Pharmathene Uk Limited Anthrax vaccine formulation and uses thereof
WO2010080188A2 (en) * 2008-10-14 2010-07-15 The Regents Of The University Of Michigan Epitope targeted anthrax vaccine
US20100183675A1 (en) * 2009-01-22 2010-07-22 Allan Watkinson Stable vaccine compositions and methods of use
US8187611B2 (en) * 2009-10-29 2012-05-29 Albert Einstein College Of Medicine Of Yeshiva University Anti-peptide antibodies that cross react with protective antigen of Bacillus anthracis and uses thereof
US20110110968A1 (en) * 2009-11-12 2011-05-12 Stanley Goldman Human optimized Bacillus anthracis protective antigen
CN101798565B (zh) * 2010-02-26 2013-08-07 中国人民解放军军事医学科学院生物工程研究所 能在芽孢表面展示pa20蛋白的炭疽芽孢杆菌及其应用
RU2633504C1 (ru) * 2016-12-27 2017-10-12 Федеральное государственное учреждение "Федеральный исследовательский центр "Фундаментальные основы биотехнологии" Российской академии наук (ФИЦ Биотехнологии РАН) Штамм E.coli - продуцент полноразмерного протективного антигена Bacillus anthracis в форме вирусоподобных частиц
RU2633508C1 (ru) * 2016-12-27 2017-10-12 Федеральное государственное учреждение "Федеральный исследовательский центр "Фундаментальные основы биотехнологии" Российской академии наук (ФИЦ Биотехнологии РАН) Штамм E. coli - продуцент изолированного домена 1 протективного антигена Bacillus anthracis в форме вирусоподобных частиц
WO2020116686A1 (ko) * 2018-12-06 2020-06-11 고려대학교 산학협력단 인간 항-antxr 키메라 항원 수용체 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2115433C1 (ru) * 1992-08-28 1998-07-20 Научно-исследовательский институт микробиологии МО РФ Вакцина сибиреязвенная комбинированная
US5677274A (en) * 1993-02-12 1997-10-14 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Anthrax toxin fusion proteins and related methods
RU2110575C1 (ru) * 1995-07-19 1998-05-10 Государственное Федеральное предприятие Государственный научный центр прикладной микробиологии Рекомбинантная плазмидная днк pro pf 5, определяющая синтез капсульного антигена fi возбудителя чумы и протективного антигена возбудителя сибирской язвы, и способ конструирования рекомбинантной плазмидной днк pro pf5
ATE418612T1 (de) 1998-07-10 2009-01-15 U S Medical Res Inst Of Infect Anthrax-impfstoff
GB0016702D0 (en) 2000-07-08 2000-08-23 Secr Defence Brit Expression system

Also Published As

Publication number Publication date
RU2270865C2 (ru) 2006-02-27
AU6930501A (en) 2002-01-21
ZA200210206B (en) 2004-03-17
CN1322134C (zh) 2007-06-20
US8313928B2 (en) 2012-11-20
US9346860B2 (en) 2016-05-24
AU2007201553A1 (en) 2007-05-03
CA2413045A1 (en) 2002-01-17
EP1808489B1 (en) 2016-03-23
WO2002004646A1 (en) 2002-01-17
AU2007201553B8 (en) 2010-06-03
US20100266639A1 (en) 2010-10-21
JP2004502460A (ja) 2004-01-29
EP1808489A1 (en) 2007-07-18
US20030170263A1 (en) 2003-09-11
AU2007201553B2 (en) 2010-04-22
JP2012010706A (ja) 2012-01-19
CA2658217A1 (en) 2002-01-17
GB0016702D0 (en) 2000-08-23
CA2413045C (en) 2016-06-21
US20130164823A1 (en) 2013-06-27
RU2004134341A (ru) 2006-05-10
RU2385348C2 (ru) 2010-03-27
US7537771B2 (en) 2009-05-26
CN1440459A (zh) 2003-09-03
EP1301606A1 (en) 2003-04-16

Similar Documents

Publication Publication Date Title
CN1322134C (zh) 表达系统
Williamson et al. A genetically engineered vaccine against the alpha-toxin of Clostridium perfringens protects mice against experimental gas gangrene
Lavie et al. PopP1, a new member of the YopJ/AvrRxv family of type III effector proteins, acts as a host-specificity factor and modulates aggressiveness of Ralstonia solanacearum
JP3370672B2 (ja) ウェルシュ菌ワクチン
JP2981286B2 (ja) 破傷風トキシンフラグメントcの発現
JP2005537796A (ja) 変性剤安定および/またはプロテアーゼ耐性シャペロン様オリゴマータンパク質、これらをコードするポリヌクレオチド、これらの使用、およびこれらの比活性を増加させる方法
CN110041437B (zh) 一种无毒性破伤风毒素和诺维梭菌α毒素重组融合蛋白
KR100338894B1 (ko) 백신조성물
CN102276730B (zh) 金黄色葡萄球菌IsdBid-TRAP融合蛋白制备方法及其应用
CN100460014C (zh) 基于尿素酶b亚单位活性片段的幽门螺杆菌疫苗及其制备方法
CN101578109A (zh) 用于坏死性肠炎的、包含突变的产气荚膜梭菌α毒素抗原的家禽疫苗及生产疫苗的方法
CA2466156C (en) Ehrlichia disulfide bond formation proteins and uses thereof
KR101765394B1 (ko) 돼지 유행성설사 바이러스의 에피토프 단백질, 이를 암호화하는 유전자를 포함하는 재조합 벡터, 이를 발현하는 형질전환체 및 이를 포함하는 돼지 유행성설사 바이러스 예방 또는 치료용 조성물
EP1931379B1 (en) Proteins with improved solubility and methods for producing and using same
AU2001269305B2 (en) Expression system
Tavares et al. Induction of neutralizing antibodies in mice immunized with an amino-terminal polypeptide of Streptococcus mutans P1 protein produced by a recombinant Bacillus subtilis strain
AU2001269305A1 (en) Expression system
KR101671528B1 (ko) 돼지 유행성 설사병 바이러스의 에피토프와 점막면역보조제를 발현하는 형질전환체 및 이를 포함하는 백신 조성물
JP2007510413A (ja) コレラ毒素のbサブユニットのための発現システム
MXPA03009306A (es) Antigenos para aumentar una respuesta inmune contra patogenos rickettsieae y ehrlichieae.
WO2002061091A1 (en) Expression facilitating nucleotide sequences for hemoglobin receptor activity from porphyromonas gingivalis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20070808